Literature DB >> 2106529

Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly.

N Hattori1, A Shimatsu, Y Kato, H Koshiyama, Y Ishikawa, H Assadian, T Tanoh, M Nagao, H Imura.   

Abstract

Plasma GH levels were determined during a 75-g oral glucose tolerance test using a highly sensitive enzyme immunoassay. Most normal subjects and patients with varying degrees of impaired glucose tolerance showed a decrease in plasma GH levels during the first 60 min. A GH rise within 60 min was observed in 3 of 37 normal subjects. The incidence of the GH rise (8%) was significantly lower than that (40%) in control experiments after water loading. The median minimum GH levels were 0.15 and 0.14 micrograms/L after glucose and water loading, respectively. Plasma GH responses to glucose ingestion were not different between normal subjects and patients with glucose intolerance. After surgery, 12 of 16 patients with acromegaly showed low basal GH levels (less than 5.0 micrograms/L). Six of the 12 patients showed normal GH responses to glucose loading (median minimum GH level, 0.21 micrograms/L) and normal plasma insulin-like growth factor-I levels. Plasma GH levels were not suppressed below 1.0 micrograms/L in the remaining 6 acromegalic patients. Determination of plasma GH levels after glucose loading by the highly sensitive enzyme immunoassay is useful for evaluating the effect of surgical treatment of acromegaly.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2106529     DOI: 10.1210/jcem-70-3-771

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly.

Authors:  Pamela U Freda; Carlos M Reyes; Abu T Nuruzzaman; Robert E Sundeen; Jeffrey N Bruce
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

2.  Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?

Authors:  Georgiana Dobri; Soamsiri Niwattisaiwong; James F Bena; Manjula Gupta; John Kirwan; Lawrence Kennedy; Amir H Hamrahian
Journal:  Endocrine       Date:  2018-11-10       Impact factor: 3.633

Review 3.  Biochemical investigations in diagnosis and follow up of acromegaly.

Authors:  Katharina Schilbach; Christian J Strasburger; Martin Bidlingmaier
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

4.  Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly.

Authors:  S Grottoli; P Razzore; D Gaia; M Gasperi; M Giusti; A Colao; E Ciccarelli; V Gasco; E Martino; E Ghigo; F Camanni
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

Review 5.  Pitfalls in the biochemical assessment of acromegaly.

Authors:  Pamela U Freda
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

Review 6.  Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly.

Authors:  Laure Cazabat; Jean-Claude Souberbielle; Philippe Chanson
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 7.  Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences.

Authors:  Martin Bidlingmaier; Pamela U Freda
Journal:  Growth Horm IGF Res       Date:  2009-10-08       Impact factor: 2.372

Review 8.  Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly.

Authors:  David Robert Clemmons
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

9.  Growth hormone/insulin-like growth factor I axis, glucose metabolism, and lypolisis but not leptin show some degree of refractoriness to short-term fasting in acromegaly.

Authors:  S Grottoli; V Gasco; A Mainolfi; G Beccuti; G Corneli; G Aimaretti; C Dieguez; F Casanueva; E Ghigo
Journal:  J Endocrinol Invest       Date:  2008-12       Impact factor: 4.256

10.  Safety and specificity of the growth hormone suppression test in patients with diabetes.

Authors:  Pedro Weslley Rosario; Maria Regina Calsolari
Journal:  Endocrine       Date:  2014-05-17       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.